K-7174 dihydrochloride iophen-2-yl)-2-(2-(m-tolyl)hydrazono)butane-1 3-dione Smiles: CC1C=CC(=CC=1)S(=O)(=O)N1CCCC[C@@H]1C(=O)NC1=NC(=CS1)C1C=CC(=CC=1)OC

Smiles: CC1C=CC(=CC=1)S(=O)(=O)N1CCCC[C@@H]1C(=O)NC1=NC(=CS1)C1C=CC(=CC=1)OC

which expressed mutated FGFR3 protein

equivalent to the effect of used with 2 times doses of EKI-785 (40 mg/kg/day)

as shown by the decreased levels of chymotrypsin-like activity and increased accumulation of ubiquitinated proteins in LNCaP cells

K-7174 dihydrochloride iophen-2-yl)-2-(2-(m-tolyl)hydrazono)butane-1 3-dione Smiles: CC1C=CC(=CC=1)S(=O)(=O)N1CCCC[C@@H]1C(=O)NC1=NC(=CS1)C1C=CC(=CC=1)OCK 7174 is a novel orally active, potent proteasome inhibitor. K 7174 exerts anti myeloma activity in vitro and in vivo by down regulating the expression of class I histone deacetylases. K 7174 kills bortezomib resistant myeloma cells carrying a 5 subunit mutation in vivo and primary cells from a patient resistant to bortezomib. K 7174 is also a GATA specific inhibitor, which may have potential application in treating anemia of chronic disease. Product